TScan Therapeutics, Inc. (TCRX) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
830 Winter Street
Waltham, MA 02451
United States of America (the)
Phone
857 399 9500
Website
Sector
Healthcare
Industry
Biotechnology
Employees
143
First IPO Date
July 16, 2021
| Name | Title | Pay | Year Born |
| Gavin MacBeath | Chief Executive Officer & Director | 818,650 | 1970 |
| Jason A. Amello | CFO, Treasurer, Principal Financial Officer & Principal Accounting Officer | 606,800 | 1968 |
| Chrystal U. Louis | Chief Medical Officer | 618,200 | 1976 |
| Zoran Zdraveski | Chief Legal & Strategy Officer and Company Secretary | 657,200 | 1970 |
| Stephen J. Elledge | Co-Founder & Chairman of Scientific Advisory Board | 0 | N/A |
| Shrikanta Chattopadhyay | Senior Vice President & Head of Translational Medicine | 0 | N/A |
| Jim Murray | Chief Development Operations Officer | 0 | N/A |
| Tomasz Kula | Co-Founder & Member of Advisory Board | 0 | N/A |
| Ann Hargraves | Chief Human Resources Officer | 0 | N/A |
| Ray Lockard | Chief Manufacturing & Quality Officer | 0 | N/A |
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company’s lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. It has a research collaboration and license agreement with Amgen Inc. to identify antigens recognized by T cells in patients with Crohn’s disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.